Published in Exp Diabetes Res on January 01, 2008
The clinical potential of C-peptide replacement in type 1 diabetes. Diabetes (2012) 0.94
A Molecular Level Understanding of Zinc Activation of C-peptide and its Effects on Cellular Communication in the Bloodstream. Rev Diabet Stud (2009) 0.82
Physiological effects and therapeutic potential of proinsulin C-peptide. Am J Physiol Endocrinol Metab (2014) 0.81
Molecular effects of C-Peptide in microvascular blood flow regulation. Rev Diabet Stud (2009) 0.77
Red blood cells express a functional endothelial nitric oxide synthase. Blood (2005) 2.30
Association of reduced red blood cell deformability and diabetic nephropathy. Kidney Int (2005) 2.23
Specific binding of proinsulin C-peptide to human cell membranes. Proc Natl Acad Sci U S A (1999) 1.91
Red-cell aggregation and red-cell deformability in diabetes. Diabetes (1976) 1.80
Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus. Diabet Med (2000) 1.63
Effects of nitric oxide on red blood cell deformability. Am J Physiol Heart Circ Physiol (2003) 1.49
Capillary recruitment in response to tissue hypoxia and its dependence on red blood cell deformability. Am J Physiol (1999) 1.37
Heterotrimeric G protein Gi is involved in a signal transduction pathway for ATP release from erythrocytes. Am J Physiol Heart Circ Physiol (2003) 1.33
C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care (2007) 1.28
Effects of C-peptide on blood flow, capillary diffusion capacity and glucose utilization in the exercising forearm of type 1 (insulin-dependent) diabetic patients. Diabetologia (1992) 1.22
Stimulation of endothelial nitric oxide synthase by proinsulin C-peptide. Nitric Oxide (2003) 1.20
The effect of human proinsulin C-peptide on erythrocyte deformability in patients with Type I diabetes mellitus. Diabetologia (1999) 1.14
Metal-activated C-peptide facilitates glucose clearance and the release of a nitric oxide stimulus via the GLUT1 transporter. Diabetologia (2007) 1.12
C-peptide stimulates rat renal tubular Na+, K(+)-ATPase activity in synergism with neuropeptide Y. Diabetologia (1996) 1.10
Biological activity of C-peptide on the skin microcirculation in patients with insulin-dependent diabetes mellitus. J Clin Invest (1998) 1.08
Differential effects of proinsulin C-peptide fragments on Na+, K+-ATPase activity of renal tubule segments. Diabetologia (1998) 1.07
C-peptide inhibits leukocyte-endothelium interaction in the microcirculation during acute endothelial dysfunction. FASEB J (2000) 1.05
C-peptide stimulates Na+, K+-ATPase via activation of ERK1/2 MAP kinases in human renal tubular cells. Cell Mol Life Sci (2004) 1.04
Effects of proinsulin C-peptide in experimental diabetic neuropathy: vascular actions and modulation by nitric oxide synthase inhibition. Diabetes (2003) 1.02
Proinsulin C-peptide increases nitric oxide production by enhancing mitogen-activated protein-kinase-dependent transcription of endothelial nitric oxide synthase in aortic endothelial cells of Wistar rats. Diabetologia (2003) 1.01
Red blood cell stimulation of platelet nitric oxide production indicated by quantitative monitoring of the communication between cells in the bloodstream. Anal Chem (2007) 0.99
C-peptide improves adenosine-induced myocardial vasodilation in type 1 diabetes patients. Am J Physiol Endocrinol Metab (2003) 0.99
C-peptide stimulates Na+,K+-ATPase activity via PKC alpha in rat medullary thick ascending limb. Diabetologia (2003) 0.98
Erythrocyte deformability in diabetes and erythrocyte membrane lipid composition. Metabolism (1990) 0.96
C-peptide prevents and improves chronic Type I diabetic polyneuropathy in the BB/Wor rat. Diabetologia (2001) 0.96
C-peptide stimulates ERK1/2 and JNK MAP kinases via activation of protein kinase C in human renal tubular cells. Diabetologia (2004) 0.95
Cellular internalization of proinsulin C-peptide. Cell Mol Life Sci (2007) 0.95
C-peptide fragments stimulate glucose utilization in diabetic rats. Cell Mol Life Sci (2004) 0.91
The C-peptide fragment EVARQ reduces glomerular hyperfiltration in streptozotocin-induced diabetic rats. Diabetes Metab Res Rev (2007) 0.90
Proinsulin C-peptide and its analogues induce intracellular Ca2+ increases in human renal tubular cells. Cell Mol Life Sci (2002) 0.88
Separate functional features of proinsulin C-peptide. Cell Mol Life Sci (2005) 0.88
C-peptide binding to human cell membranes: importance of Glu27. Biochem Biophys Res Commun (2001) 0.84
Effects of nitric oxide and prostacyclin on deformability and aggregability of red blood cells of rats ex vivo and in vitro. J Physiol Pharmacol (1999) 0.81
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet (2012) 3.48
Pilot study for assessment of optimal frequency for changing catheters in insulin pump therapy-trouble starts on day 3. J Diabetes Sci Technol (2010) 2.48
Clinical assessment of the accuracy of blood glucose measurement devices. Curr Med Res Opin (2012) 2.18
Psychological insulin resistance in type 2 diabetes patients regarding oral antidiabetes treatment, subcutaneous insulin injections, or inhaled insulin. Diabetes Technol Ther (2013) 2.04
Accuracy evaluation of five blood glucose monitoring systems obtained from the pharmacy: a European multicenter study with 453 subjects. Diabetes Technol Ther (2011) 1.89
Direct measurements of the permeability surface area for insulin and glucose in human skeletal muscle. J Clin Endocrinol Metab (2003) 1.75
Analysis of the environmental impact of insulin infusion sets based on loss of resources with waste. J Diabetes Sci Technol (2011) 1.74
Dynamic electrochemistry corrects for hematocrit interference on blood glucose determinations with patient self-measurement devices. J Diabetes Sci Technol (2011) 1.61
Crossing the barrier: net flux of 27-hydroxycholesterol into the human brain. J Lipid Res (2005) 1.60
Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol (2005) 1.60
Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care (2013) 1.55
Impact of posture and fixation technique on impedance spectroscopy used for continuous and noninvasive glucose monitoring. Diabetes Technol Ther (2004) 1.53
Differences in the dose accuracy of insulin pens. J Diabetes Sci Technol (2008) 1.52
Impact of insulin on microvascular blood flow and endothelial cell function in the postprandial state in patients with Type 1 diabetes. J Diabetes Complications (2005) 1.50
High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. Diabetes Technol Ther (2006) 1.48
Review of approved pioglitazone combinations for type 2 diabetes. Expert Opin Pharmacother (2011) 1.43
Determination of nitrotyrosine concentrations in plasma samples of diabetes mellitus patients by four different immunoassays leads to contradictive results and disqualifies the majority of the tests. Clin Chem Lab Med (2009) 1.42
Association of COLIA1 Sp1 polymorphism with the effect of subcutaneously injected recombinant hGH in GH-deficient adults. Pharmacogenomics (2008) 1.39
Splanchnic regulation of glucose production. Annu Rev Nutr (2007) 1.39
Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol (2007) 1.38
Development and validation of a new measure to evaluate psychological resistance to insulin treatment. Diabetes Care (2007) 1.34
C-peptide exerts beneficial effects on myocardial blood flow and function in patients with type 1 diabetes. Diabetes (2002) 1.32
The contribution of visceral adipose tissue to splanchnic cortisol production in healthy humans. Diabetes (2005) 1.32
C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care (2007) 1.28
Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Diabetes Care (2004) 1.26
Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complications (2006) 1.21
Stimulation of endothelial nitric oxide synthase by proinsulin C-peptide. Nitric Oxide (2003) 1.20
Novel route for elimination of brain oxysterols across the blood-brain barrier: conversion into 7alpha-hydroxy-3-oxo-4-cholestenoic acid. J Lipid Res (2007) 1.20
Comparison of the dose accuracy of prefilled insulin pens. J Diabetes Sci Technol (2009) 1.20
Hematocrit interference of blood glucose meters for patient self-measurement. J Diabetes Sci Technol (2013) 1.18
C-peptide prevents glomerular hypertrophy and mesangial matrix expansion in diabetic rats. Nephrol Dial Transplant (2005) 1.10
Pulmonary insulin delivery by means of the Technosphere drug carrier mechanism. Expert Opin Drug Deliv (2005) 1.08
Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk--the PIOSTAT Study. Metabolism (2007) 1.07
Reduction of postprandial glycemic excursions in patients with type 1 diabetes: a novel human insulin formulation versus a rapid-acting insulin analog and regular human insulin. J Diabetes Sci Technol (2011) 1.05
Rotational stability of a single-piece hydrophobic acrylic intraocular lens: new method for high-precision rotation control. J Cataract Refract Surg (2007) 1.05
Molecular effects of proinsulin C-peptide. Biochem Biophys Res Commun (2002) 1.04
Role of intact proinsulin in diagnosis and treatment of type 2 diabetes mellitus. Diabetes Technol Ther (2004) 1.03
Effects of proinsulin C-peptide in experimental diabetic neuropathy: vascular actions and modulation by nitric oxide synthase inhibition. Diabetes (2003) 1.02
Amelioration of sensory nerve dysfunction by C-Peptide in patients with type 1 diabetes. Diabetes (2003) 1.02
Blood glucose meters employing dynamic electrochemistry are stable against hematocrit interference in a laboratory setting. J Diabetes Sci Technol (2013) 1.01
Determination of hematocrit interference in blood samples derived from patients with different blood glucose concentrations. J Diabetes Sci Technol (2013) 1.01
High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazone. J Diabetes Sci Technol (2010) 1.00
Biological background and role of adiponectin as marker for insulin resistance and cardiovascular risk. Clin Lab (2005) 0.99
C-peptide improves adenosine-induced myocardial vasodilation in type 1 diabetes patients. Am J Physiol Endocrinol Metab (2003) 0.99
Short communication: high prevalence of the cytochrome P450 2C8*2 mutation in Northern Ghana. Trop Med Int Health (2005) 0.98
Novel LC-MS/MS method for assay of 7alpha-hydroxy-4-cholesten-3-one in human plasma. Evidence for a significant extrahepatic metabolism. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 0.98
Coverage of postprandial blood glucose excursions with inhaled technosphere insulin in comparison to subcutaneously injected regular human insulin in subjects with type 2 diabetes. Diabetes Care (2007) 0.98
Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance. Clin Lab (2003) 0.97
Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk. Diab Vasc Dis Res (2008) 0.97
Molecular and cellular effects of C-peptide--new perspectives on an old peptide. Exp Diabesity Res (2004) 0.96
Evaluation of dexterity in insulin-treated patients with type 1 and type 2 diabetes mellitus. J Diabetes Sci Technol (2011) 0.96
ProAct study: new features of insulin pumps improve diabetes management and glycemic control in patients after transition of continuous subcutaneous insulin infusion systems. Diabetes Technol Ther (2013) 0.96
Predictors of cognitive impairment in type 1 diabetes. Psychoneuroendocrinology (2007) 0.95
Evaluation of CGMS during rapid blood glucose changes in patients with type 1 diabetes. Diabetes Technol Ther (2006) 0.93
Splanchnic balance of free fatty acids, endocannabinoids, and lipids in subjects with nonalcoholic fatty liver disease. Gastroenterology (2010) 0.93
Intra-individual variability of the metabolic effect of a novel rapid-acting insulin (VIAject) in comparison to regular human insulin. J Diabetes Sci Technol (2008) 0.93
Elevated intact proinsulin levels are indicative of Beta-cell dysfunction, insulin resistance, and cardiovascular risk: impact of the antidiabetic agent pioglitazone. J Diabetes Sci Technol (2011) 0.92
Comparison of patient preference for two insulin injection pen devices in relation to patient dexterity skills. J Diabetes Sci Technol (2012) 0.92
The precision study: examining the inter- and intra-assay variability of replicate measurements of BGStar, iBGStar and 12 other blood glucose monitors. Expert Opin Med Diagn (2013) 0.92
Association of high-sensitive C-reactive protein with advanced stage beta-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitus. Clin Chem Lab Med (2006) 0.91
Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects. Expert Opin Pharmacother (2007) 0.91
Loss of temporal lobe beta power in young adults with type 1 diabetes mellitus. Neuroreport (2002) 0.90
The switch from sulfonylurea to preprandial short- acting insulin analog substitution has an immediate and comprehensive beta-cell protective effect in patients with type 2 diabetes mellitus. Diabetes Technol Ther (2006) 0.90
Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects. Expert Rev Cardiovasc Ther (2006) 0.89
Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study. Cardiovasc Diabetol (2011) 0.88
Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer. Anticancer Drugs (2006) 0.88
C-Peptide reverses nociceptive neuropathy in type 1 diabetes. Diabetes (2006) 0.88
Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2. Microcirculation (2005) 0.88
Influence of C-peptide on early glomerular changes in diabetic mice. Diabetes Metab Res Rev (2006) 0.88
Intact and total proinsulin: new aspects for diagnosis and treatment of type 2 diabetes mellitus and insulin resistance. Clin Lab (2004) 0.87
The IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions. Diabetes Technol Ther (2008) 0.87
Association of sulphonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies. Diab Vasc Dis Res (2013) 0.87
PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia. Diabetes Technol Ther (2011) 0.87
Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control. Exp Diabetes Res (2012) 0.86
C-peptide and captopril are equally effective in lowering glomerular hyperfiltration in diabetic rats. Nephrol Dial Transplant (2004) 0.86